Cholera Vaccines Market Size, Share & Trends Analysis Report By Product (Dukoral, Shanchol, Vaxchora), By Region (North America, APAC, Europe, MEA, Latin America), And Segment Forecasts, 2018 - 2025

Table of Contents

Chapter 1 Executive Summary
                 1.1 Market Snapshot
Chapter 2 Methodology and Scope
                 2.1 Information Procurement
                     2.1.1 Purchased database:
                     2.1.2 GVR’s internal database
                 2.2 Research Methodology
                 2.3 Geographic Scope & Assumptions
                 2.4 Region-wise Market Calculation
                     2.4.1 Region-wise market: Base estimates
                     2.4.2 Global market: CAGR calculation
                 2.5 Region-based segment share calculation
                 2.6 List of Secondary Sources
Chapter 3 Cholera Vaccines Market Variables, Trends & Scope
                 3.1 Market segmentation & scope
                 3.2 Market size and growth prospects
                     3.2.1 Market Driver Analysis
                         3.2.1.1 Rise in importance of immunization across the globe
                         3.2.1.2 High incidence of cholera
                         3.2.1.3 Rise in number of initiatives to control cholera
                     3.2.2 Market restraint analysis
                         3.2.2.1 Adverse effects of vaccines
                 3.3 Penetration & Growth Prospect Mapping
                 3.4 Cholera Vaccines - SWOT Analysis, By Factor (political & legal, economic and technological)
                 3.5 Industry Analysis - Porter’s
Chapter 4 Cholera Vaccines Market: Product Estimates & Trend Analysis
                 4.1 Cholera Vaccines Market: Product Movement Analysis
                 4.2 Dukoral
                     4.2.1 Dukoral market, 2013 - 2025 (USD Million)
                 4.3 Shanchol
                     4.3.1 Shanchol market, 2013 - 2025 (USD Million)
                 4.4 Vaxchora
                     4.4.1 Vaxchora market, 2013 - 2025 (USD Million)
                 4.5 Others
                     4.5.1 Other cholera vaccines market, 2013 - 2025 (USD Million)
Chapter 5 Cholera Vaccines Market: Regional Estimates & Trend Analysis
                 5.1 Cholera vaccines market share by region, 2017 & 2025
                 5.2 North America
                     5.2.1 North America cholera vaccines market, 2013 - 2025 (USD Million)
                     5.2.2 U.S.
                         5.2.2.1 U.S. cholera vaccines market, 2013 - 2025 (USD Million)
                     5.2.3 Canada
                         5.2.3.1 Canada cholera vaccines market, 2013 - 2025 (USD Million)
                 5.3 Europe
                     5.3.1 Europe cholera vaccines market, 2013 - 2025 (USD Million)
                     5.3.2 Germany
                         5.3.2.1 Germany cholera vaccines market, 2013 - 2025 (USD Million)
                     5.3.3 U.K.
                         5.3.3.1 U.K. cholera vaccines market, 2013 - 2025 (USD Million)
                 5.4 Asia Pacific
                     5.4.1 Asia Pacific cholera vaccines market, 2013 - 2025 (USD Million)
                     5.4.2 China
                         5.4.2.1 China cholera vaccines market, 2013 - 2025 (USD Million)
                     5.4.3 India
                         5.4.3.1 India cholera vaccines market, 2013 - 2025 (USD Million)
                 5.5 Latin America
                     5.5.1 Latin America cholera vaccines market, 2013 - 2025 (USD Million)
                     5.5.2 Brazil
                         5.5.2.1 Brazil cholera vaccines market, 2013 - 2025 (USD Million)
                 5.6 Middle East & Africa (MEA)
                     5.6.1 MEA cholera vaccines market, 2013 - 2025 (USD Million)
                     5.6.2 South Africa
                         5.6.2.1 South Africa cholera vaccines market, 2013 - 2025 (USD Million)
Chapter 6 Competitive Landscape
                 6.1 Strategy Framework
                 6.2 Company Profiles
                     6.2.1 Shantha Biotechnics Private Limited
                         6.2.1.1 Company overview
                         6.2.1.2 Financial performance
                         6.2.1.3 Product benchmarking
                         6.2.1.4 Strategic initiatives
                     6.2.2 Valneva SE
                         6.2.2.1 Company overview
                         6.2.2.2 Financial performance
                         6.2.2.3 Product benchmarking
                         6.2.2.4 Strategic initiatives
                     6.2.3 PaxVax, Inc.
                         6.2.3.1 Company overview
                         6.2.3.2 Financial performance
                         6.2.3.3 Product benchmarking
                         6.2.3.4 Strategic initiatives
                     6.2.4 Astellas Pharma, Inc.
                         6.2.4.1 Company overview
                         6.2.4.2 Product benchmarking
                         6.2.4.3 Strategic initiatives
                     6.2.5 Merck & Co., Inc.
                         6.2.5.1 Company overview
                         6.2.5.2 Financial performance
                         6.2.5.3 Product benchmarking
                         6.2.5.4 Strategic initiatives
                     6.2.6 GlaxoSmithKline plc (GSK)
                         6.2.6.1 Company overview
                         6.2.6.2 Financial performance
                         6.2.6.3 Product benchmarking
                         6.2.6.4 Strategic initiatives
                     6.2.7 Pfizer, Inc.
                         6.2.7.1 Company overview
                         6.2.7.2 Financial performance
                         6.2.7.3 Product benchmarking
                         6.2.7.4 Strategic initiatives
                     6.2.8 Takeda Pharmaceutical Co., Ltd.
                         6.2.8.1 Company overview
                         6.2.8.2 Financial performance
                         6.2.8.3 Product benchmarking
                         6.2.8.4 Strategic initiatives
                     6.2.9 Emergent BioSolutions, Inc.
                         6.2.9.1 Company overview
                         6.2.9.2 Product benchmarking
                         6.2.9.3 Strategic initiatives
                     6.2.10 AstraZeneca
                         6.2.10.1 Company overview
                         6.2.10.2 Financial performance
                         6.2.10.3 Product benchmarking
                         6.2.10.4 Strategic initiatives
                     6.2.11 Mitsubishi Tanabe Pharma Corporation
                         6.2.11.1 Company overview
                         6.2.11.2 Financial performance
                         6.2.11.3 Product benchmarking
                         6.2.11.4 Strategic initiatives

List of Tables

TABLE 1 Country share estimation
TABLE 2 North America cholera vaccines market, by product, 2013 - 2025 (USD Million)
TABLE 3 U.S. cholera vaccines market, by product, 2013 - 2025 (USD Million)
TABLE 4 Canada cholera vaccines market, by product, 2013 - 2025 (USD Million)
TABLE 5 Europe cholera vaccines market, by product, 2013 - 2025 (USD Million)
TABLE 6 Germany cholera vaccines market, by product, 2013 - 2025 (USD Million)
TABLE 7 U.K. cholera vaccines market, by product, 2013 - 2025 (USD Million)
TABLE 8 Asia Pacific cholera vaccines market, by product, 2013 - 2025 (USD Million)
TABLE 9 China cholera vaccines market, by product, 2013 - 2025 (USD Million)
TABLE 10 India cholera vaccines market, by product, 2013 - 2025 (USD Million)
TABLE 11 Latin America cholera vaccines market, by product, 2013 - 2025 (USD Million)
TABLE 12 Brazil cholera vaccines market, by product, 2013 - 2025 (USD Million)
TABLE 13 MEA cholera vaccines market, by product, 2013 - 2025 (USD Million)
TABLE 14 South Africa cholera vaccines market, by product, 2013 - 2025 (USD Million)

List of Figures

FIG. 1 Market summary
FIG. 2 Market research process
FIG. 3 Information procurement
FIG. 4 Value chain-based sizing & forecasting
FIG. 5 QFD modelling for market share assessment
FIG. 6 Market trends & outlook
FIG. 7 Market segmentation & scope
FIG. 8 Global cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 9 Market driver relevance analysis (Current & future impact)
FIG. 10 Administration of Dukoral or Shanchol in post-licensure oral cholera vaccination campaigns globally, 1997 - 2014
FIG. 11 Reported cases of cholera by continent and by year (2011-2016)
FIG. 12 Market restrain relevance analysis (Current & future impact)
FIG. 13 Penetration & growth prospect mapping
FIG. 14 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 15 Porter’s Five Forces Analysis
FIG. 16 Cholera vaccines market product outlook key takeaways
FIG. 17 Cholera vaccines market: Product movement analysis
FIG. 18 Global Dukoral market, 2013 - 2025 (USD Million)
FIG. 19 Global Shanchol market, 2013 - 2025 (USD Million)
FIG. 20 Global Vaxchora market, 2013 - 2025 (USD Million)
FIG. 21 Global other cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 22 Regional market place: Key takeaways
FIG. 23 Cholera vaccines market: Regional movement analysis
FIG. 24 North America cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 25 U.S. cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 26 Canada cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 27 Europe cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 28 Germany cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 29 U.K. cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 30 Asia Pacific cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 31 China cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 32 India cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 33 Latin America cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 34 Brazil cholera vaccines market, 2015 - 2025 (USD Million)
FIG. 35 MEA cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 36 South Africa cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 37 Strategy framework